While accurate blood tests that measure biomarkers like pTau-217 provide a proxy estimate of beta-amyloid in the brain, that alone does not predict decline in healthy people. Right now, these tests are only used to rule out Alzheimer’s as a cause of cognitive decline, or to confirm a diagnosis.